SCHEMBL2783376

SCHEMBL2783376

CCCc1c[nH]c2ncnc(Cl)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.53
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
AURKA O14965 1/20 0.38
IRAK4 Q9NWZ3 2/20 0.36
TRPA1 O75762 2/20 0.36
STK3 Q13188 4/20 0.36
STK4 Q13043 3/20 0.36
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
CHUK O15111 1/20 0.36
PDPK1 O15530 1/20 0.36
DYRK3 O43781 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
NTRK1 P04629 1/20 0.36
PRKCG P05129 1/20 0.36
INSR P06213 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4780230 0.86 CHEK1 (0.56) CHEK1CYP3A4CYP2C19AURKAIRAK4
SCHEMBL16765811 0.83 CHEK1 (0.49) CHEK1AURKAIRAK4TRPA1STK3
SCHEMBL24345183 0.81 CHEK1 (0.58) CHEK1AURKAIRAK4TRPA1STK3
SCHEMBL20195284 0.80 CHEK1 (0.49) CHEK1AURKAIRAK4TRPA1STK3
SCHEMBL3236479 0.79 CHEK1 (0.56) CHEK1AURKAIRAK4STK3STK4
SCHEMBL16765141 0.76 CHEK1 (0.49) CHEK1AURKAIRAK4TRPA1STK3
SCHEMBL12065776 0.76 CHEK1 (0.49) CHEK1CYP3A4CYP2C19AURKAIRAK4
SCHEMBL3285768 0.76 CHEK1 (0.42) CHEK1AURKAIRAK4TRPA1STK3
SCHEMBL16765827 0.75 CHEK1 (0.51) CHEK1CHUKROCK2CSNK2A1ROCK1
SCHEMBL2696119 0.75 LRRK2 (0.50) CHEK1AURKASTK3CDC7PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010066629-A2 NOVEL AZAINDOLES F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 WO disclosed
WO-2010066629-A2 NOVEL AZAINDOLES F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 WO disclosed
US-20100144758-A1 AZAINDOLE P2X3 AND P2X2/3 MODULATORS DILLON MICHAEL PATRICK 2010-06-10 US disclosed
US-20100144758-A1 AZAINDOLE P2X3 AND P2X2/3 MODULATORS DILLON MICHAEL PATRICK 2010-06-10 US disclosed
US-20100144758-A1 AZAINDOLE P2X3 AND P2X2/3 MODULATORS DILLON MICHAEL PATRICK 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144758-A1 AZAINDOLE P2X3 AND P2X2/3 MODULATORS P2RX3, P2RX2, P2RX7 CHEK1 4153/4885CYP3A4 1815/4885CYP2C19 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.